Related Experiment Videos
Structural changes in cardiovascular disease
1Department of Medicine, University of Minnesota Medical School, Minneapolis 55455, USA.
Insights
Structural changes in the heart and blood vessels are key to cardiovascular disease. Angiotensin-converting enzyme (ACE) inhibitors show promise in altering disease progression by targeting these remodeling processes.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Structural alterations in the heart and vasculature are a common pathway for cardiovascular disease morbidity and mortality.
- Current therapeutic strategies are increasingly focusing on these structural changes.
Purpose of the Study:
- To explore the role of interventions, particularly angiotensin-converting enzyme (ACE) inhibitors, in modifying cardiovascular remodeling.
- To highlight the importance of addressing structural abnormalities in chronic cardiovascular diseases.
Main Methods:
- Review of existing literature on the effects of ACE inhibitors on left ventricular and vascular remodeling.
- Discussion of potential mechanisms of action for ACE inhibitors, including effects on angiotensin II and bradykinin.
- Exploration of other agents that may complement ACE inhibitor actions.
Main Results:
- ACE inhibitors demonstrate a significant effect on both left ventricular and vascular remodeling.
- The precise mechanisms by which ACE inhibitors exert their effects (e.g., angiotensin II reduction, bradykinin increase) require further elucidation.
- Other therapeutic agents may also play a role in inhibiting adverse remodeling processes.
Conclusions:
- Future therapies for chronic cardiovascular diseases must prioritize structural abnormalities.
- Targeted interventions aimed at specific structural changes hold potential to profoundly impact disease outcomes.
- ACE inhibitors represent a promising class of drugs for altering the natural history of cardiovascular diseases by targeting remodeling.
Abstract:
The growing emphasis on structural alterations in the heart and vasculature as a critical common pathway toward morbidity and mortality in a wide variety of cardiovascular diseases has opened the door to new interventions that might fundamentally affect these processes. Converting enzyme inhibitors, because of their demonstrable effect on both left ventricular and vascular remodeling, are attractive agents to alter the natural history of these diseases. Whether the effect of converting enzyme inhibitors is mediated by a reduction of angiotensin II, an increase in bradykinin, or other local growth factors remains to be established. Other agents may share or complement the actions of angiotensin-converting enzyme (ACE) inhibitors in inhibiting these unwanted remodeling processes. It is clear that the future of therapy for chronic cardiovascular diseases must take into consideration the structural abnormalities that in the past have been given inadequate attention. New and more targeted therapy to alter specific structural changes may profoundly affect the natural history of these diseases.